

# A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More Potent

Lykke Pedersen<sup>1,2</sup>, Peter H Hagedorn<sup>2,3</sup>, Marie Wickström Lindholm<sup>3</sup> and Morten Lindow<sup>1,2,3</sup>

Antisense oligonucleotides complementary to RNA targets promise generality and ease of drug design. The first systemically administered antisense drug was recently approved for treatment and others are in clinical development. Chemical modifications that increase the hybridization affinity of oligonucleotides are reasoned to confer higher potency, *i.e.*, modified oligonucleotides can be dosed at lower concentrations to achieve the same effect. Surprisingly, shorter and less affine oligonucleotides sometimes display increased potency. To explain this apparent contradiction, increased uptake or decreased propensity to form structures have been suggested as possible mechanisms. Here, we provide an alternative explanation that invokes only the kinetics behind oligonucleotide-mediated cleavage of RNA targets. A model based on the law of mass action predicts, and experiments support, the existence of an optimal binding affinity. Exaggerated affinity, and not length *per se*, is detrimental to potency. This finding clarifies how to optimally apply high-affinity modifications in the discovery of potent antisense oligonucleotide drugs.

*Molecular Therapy—Nucleic Acids* (2014) 3, e149; doi:10.1038/mtna.2013.72; published online 18 February 2014

**Subject Category:** Antisense oligonucleotides

## Introduction

Antisense oligonucleotides can be used to elicit RNase H-mediated cleavage and decay of target RNA.<sup>1</sup> RNase H is a non-sequence-specific enzyme that recognizes RNA–DNA heteroduplexes and specifically cleaves the RNA strand.<sup>2</sup> Although the basic principle behind antisense was realized early,<sup>3</sup> the binding affinity and pharmacokinetics of natural, unmodified, oligonucleotides were found to be insufficient for their use as systemic drugs.<sup>4</sup> Therefore, central to the development of oligonucleotides for therapeutics lies efforts in medicinal chemistry to improve oligonucleotide stability, biodistribution, as well as RNA binding affinity. With the introduction of high-affinity locked nucleic acids (LNAs),<sup>5,6</sup> oligonucleotides as short as 12nt in length have been reported to achieve sufficient binding affinity to potently silence their targets.<sup>7,8</sup> Other types of modifications, such as 2'-O-methoxyethyl and 2'-O-methyl,<sup>9</sup> are also in use, although here 20nt are usually needed for sufficient binding affinity. Since none of these modifications allow recruitment of RNase H, modified oligonucleotides are typically designed as gapmers, with high-affinity nucleotides in the flanks and a central gap of DNAs. A gapmer targeting *apolipoprotein B* (*APOB*), with five 2'-O-methoxyethyls in the flanks and a central stretch of 10 DNAs, was recently approved for the treatment of homozygous familial hypercholesterolemia,<sup>10</sup> and many others are in clinical development.<sup>4</sup> Improving on the first-generation unmodified DNA oligonucleotides, it has been generally observed that high-affinity modifications improve the potency of the antisense drug candidate, with LNA and 2'-O-methoxyethyl resulting in better potencies than 2'-O-methyl and unmodified bases.<sup>4,11</sup> With such an apparent proportionality between the affinity and potency of antisense oligonucleotides, it would be expected that longer oligonucleotides

tend to have higher potency than shorter ones, since more nucleotides increase affinity by allowing more hydrogen bonds and additional base stackings. But this simple expectation is contradicted by experimental observations. To date, potency has been evaluated and reported for LNA-modified oligonucleotides between 12 and 20nt in length with between 2 and 5 LNAs in the flanks. When stratifying by length it has been observed that shorter oligonucleotides targeting the same target site has increased potency compared with longer versions.<sup>7,8,11–13</sup> So far, no mechanism for this seemingly counterintuitive increase in potency with decreases in affinity has been demonstrated. Suggested explanations include variations in gapsize,<sup>7</sup> less tendency to self-complementarity or improved pharmacokinetics of shorter oligonucleotides.<sup>12</sup>

In this paper, we ask if simple enzyme kinetics can account for these observations. Kinetic models have previously been successfully applied to explain and understand important actions of small RNAs or oligonucleotide-induced degradation of messenger RNAs (mRNAs). In the work by Herschlag,<sup>14</sup> the specificity of ribozymes and RNase H-recruiting oligonucleotides is investigated as a function of the length of their recognition sequence. As the sequence is made longer, the dissociation of mismatched duplexes is expected to become slower, and so the rate of cleavage for these mismatched RNAs will be increased relative to that of the intended target. This suggests the existence of an optimal length to achieve maximal discrimination between intended and unintended, mismatched, targets. Larsson *et al.*<sup>15</sup> examined differences in the maximal achievable knockdown of mRNAs by small interfering RNA (siRNA) and microRNA. They demonstrate that mRNAs with high turnover rates are less efficaciously downregulated since the relative contribution of an siRNA/microRNA to the degradation rate of


The first two authors contributed equally to this work.

<sup>1</sup>The Bioinformatics Centre, Department of Biology, University of Copenhagen, Copenhagen, Denmark; <sup>2</sup>Center for Computational and Applied Transcriptomics, Department of Biology, University of Copenhagen, Copenhagen, Denmark; <sup>3</sup>Santaris Pharma A/S, Research Division, Hørsholm, Denmark Correspondence: Morten Lindow, The Bioinformatics Centre, Department of Biology, University of Copenhagen, DK-2200 Copenhagen, Denmark. E-mail: [mol@santaris.com](mailto:mol@santaris.com).

**Keywords:** kinetic model; oligonucleotide affinity; potency

Received 10 September 2013; accepted 29 November 2013; advance online publication 18 February 2014. doi:10.1038/mtna.2013.72





**Figure 2** Model solutions and identification of an optimal binding affinity. **(a,b)** Time-resolved simulation of the relative concentrations of key species in the reaction scheme from **Figure 1**. Oligonucleotide (O) is added at time  $t = 0$  minute at a concentration of **(a)** 0.1 and **(b)** 100 nmol/l. **(c)** The relative total target concentration ( $T_{rel}$ ) as a function of total oligonucleotide concentration at typical parameter settings (**Table 1**). Dashed lines indicate efficacy (horizontal) and half-maximal effect concentration ( $EC_{50}$ ) (vertical). Arrows indicate the total oligonucleotide concentrations used in **(a)** and **(b)**. **(d)** The  $EC_{50}$  as a function of the dissociation constant for the OT complex. A low dissociation constant between the oligonucleotide and the target ( $K_{dOT}$ ) corresponds to a high binding affinity. Dashed line: no coupling between  $k_{OT \rightarrow O+T}$  and  $k_{OC \rightarrow O+C}$ . Solid line:  $k_{OT \rightarrow O+T} = \alpha \cdot k_{OC \rightarrow O+C}$ . **(e–g)** Experimental knockdown as a function of calculated  $\Delta G^\circ$ : **(e)** for 21 oligonucleotides at 2 nmol/l targeted against the luciferase firefly gene,<sup>7</sup> **(f)** for 14 oligonucleotides at 3 nmol/l targeted against the glucocorticoid receptor,<sup>13</sup> and **(g)** for 23 oligonucleotides at 1 nmol/l targeted against *apolipoprotein B* (APOB), **(h)** 4 oligonucleotides at 0.06  $\mu\text{mol/l}$  and 1.5  $\mu\text{mol/l}$  against *PCSK9*. Legend indicates oligonucleotide lengths. Target messenger RNA concentrations are measured by **(e)** luciferase assay and **(f,g,h)** quantitative reverse transcriptase–polymerase chain reaction. Dots are experimental data and gray lines are a least squares fit to a second-order polynomial with  $P$  values and vertex for the fit in each of the panels **e–h**.

transcriptase–polymerase chain reaction (PCR). We use the model to calculate the steady-state ratio ( $T_{rel}$ ) of target levels in treated versus untreated (or control treated) cells as a function of  $O_t$ . This yields a dose–response curve (**Figure 2c**), with an efficacy (the maximum decrease in  $T_{rel}$ ) and potency, dependent on the choice of model parameter values (**Supplementary Figures S1 and S2**). Potency is defined as the inverse of the half-maximal effect concentration,  $EC_{50}$ , which in mathematical terms is defined as:

$$EC_{50} = \left( O_t \left| T_{rel} = \frac{\text{Efficacy}}{2} + T_{rel,min} \right. \right) \quad (1)$$

with  $T_{rel,min} = \lim_{O_t \rightarrow \infty} T_{rel}$ . According to the model, the efficacy of an oligonucleotide can be increased, by increasing the rate by which the OT complex recruits RNase H and the rate by which RNase H cleaves the target (**Supplementary Figure S2**). However, changing the formation rate of the OT complex has no effect on the efficacy. In general, a high concentration of RNase H improves both the efficacy and the potency, and a low target production and a low basal (non-oligonucleotide mediated) target degradation rate also improves efficacy and potency. Therefore, cells with high concentrations of RNase

H and targets with low production and degradation rates are preferred for antisense oligonucleotides therapeutics.

### The kinetic model predicts the existence of an optimal binding affinity

Examining  $EC_{50}$  as a function of the binding affinity between the oligonucleotide and the target, we see that  $EC_{50}$  decreases with increasing affinity to a certain point where the effect of increased affinity reaches a plateau (**Figure 2d**, dashed line). Here, the affinity is defined as the inverse of the dissociation constant between the oligonucleotide and the target ( $K_{dOT}$ ), which is in turn defined by the ratio between the dissociation and association rate of OT, *i.e.*,  $K_{dOT} = k_{OT \rightarrow O+T} / k_{O+T \rightarrow OT}$ . In principle,  $K_{dOT}$  can change if either of the association or dissociation rates are changed. The association rate can be interpreted as the frequency by which a collision between the oligonucleotide and the target site will be aligned sterically in such a way as to allow formation of base pairs and thus binding. For oligonucleotides, this collision frequency is primarily limited by the accessibility of the RNA, *i.e.*, the secondary structure of the targeted RNA.<sup>20–23</sup> The dissociation rate is interpreted as how often the energy of the thermal vibrations will be able to overcome the free energy of hybridization and

allow dissociation. In practice, affinity is altered by adjusting the number of base pairs (by shortening or lengthening the oligonucleotide) or by adjusting the strength of each base pair (by adding or removing high-affinity modifications). Hence, we model affinity changes by modulating the dissociation rate,  $k_{OT \rightarrow O+T}$ , while keeping the association rate,  $k_{O+T \rightarrow OT}$ , constant. The experimental range of  $K_{dOT}$ -values is taken from the literature.<sup>16</sup>

Next, we reasoned that there is an important coupling between the rate at which an oligonucleotide dissociates from an uncleaved target and the rate at which it leaves the cleaved target. After the enzyme hydrolyzes the phosphodiester backbone of the RNA target, the dissociation becomes a two-step process: either the left or right end leaves first (Figure 3). The slowest of these processes will be rate-limiting for the recycling of free oligonucleotide (denoted as  $k_{OC \rightarrow O+C}$ ). If the dissociation rate from the intact target ( $k_{OT \rightarrow O+T}$ ) is decreased (e.g., due to increased affinity),  $k_{OC \rightarrow O+C}$  must also be decreased. Moreover, since after cleavage, there will be fewer base pairs (and thus fewer hydrogen bonds and stacking interactions) to break than when dissociating from an intact target,  $k_{OC \rightarrow O+C} < k_{OT \rightarrow O+T}$ . This is included in the model by the simple, linear relation  $k_{OC \rightarrow O+C} = k_{OT \rightarrow O+T}/\alpha$ , where  $0 < \alpha < 1$ . A high value of  $\alpha$  models a case where the oligonucleotide leaves the cleaved target at a rate close to the rate at which it dissociates from the intact target. Intriguingly, irrespective of the actual value of  $\alpha$ , the introduction of this coupling between  $k_{OT \rightarrow O+T}$  and  $k_{OC \rightarrow O+C}$  reveals a relationship between  $EC_{50}$  and affinity (Figure 2d, solid line), where there is an optimal affinity beyond which additional added affinity is detrimental to potency. Intuitively phrased, the higher the affinity toward the uncleaved target, the higher the affinity will also be to either parts of the cleaved target. And a high affinity toward the cleaved target results in a slow release of enzyme and oligonucleotide, which stalls the catalytic cycle and therefore reduces potency.


The ODEs behind the model (Eqs. 1–7) allow both deterministic, time-resolved, simulations (Figure 2a,b) and derivation of algebraic solutions. We also explored stochastic simulations<sup>24</sup> of the ODEs. This reproduced the existence of an optimal affinity (Supplementary Figures S3 and S4), supporting the deterministic solution to the ODEs.

### Experimental support for an optimal binding affinity

To investigate if the model-predicted existence of an optimal affinity could be confirmed by experiments, we reanalyzed data from two published studies evaluating the ability of different oligonucleotides to reduce luciferase (*LUC*) mRNA in HeLa cells<sup>7</sup> and glucocorticoid receptor (*GR*) mRNA in Hep3B cells,<sup>13</sup> respectively (Supplementary Material S1 for oligonucleotide data and Supplementary Material S2 for mRNA sequences). Using a validated nearest-neighbor model for LNA-modified oligonucleotide-binding to RNA (see Methods), we calculated standard free energies of binding at 37 °C,  $\Delta G^\circ$ , for those oligonucleotides in the two studies where both target knockdown efficiency and temperatures of melting,  $T_m$  (needed for the validation), were available. Plotting  $\Delta G^\circ$  values calculated in this manner against the realized target knockdown in each study (Figure 2e,f) confirms the model's prediction of a region of optimal affinity (Figure 2d). We note that the model

predictions of  $EC_{50}$  as a function of  $K_{dOT}$  closely resembles a parabola over the experimentally observed affinity range (Figure 2d and Supplementary Figure S5). To estimate an optimal  $\Delta G^\circ$  from the data we therefore fit a second-order polynomial by least squares (gray lines in Figure 2e,f). As seen in Figure 2e,f, the optimal  $\Delta G^\circ$  is estimated to  $-23$  and  $-19$  kcal/mol, respectively. Furthermore, to confirm the presence of an affinity optimum also for a well-established antisense target of clinical importance,<sup>10</sup> and independently of the length of the oligonucleotides, we synthesized and evaluated a set of compounds consisting of four 12-mers, two 13-mers, and seventeen 14-mers complementary to the *APOB* mRNA. The 23 oligonucleotides cover a broad range of predicted affinities. The ability of all the oligonucleotides to reduce the levels of *APOB* mRNA in HuH-7 cells were quantified by quantitative reverse transcriptase-PCR. Similar to the historic published data (Figure 2e,f), this experiment also showed that oligonucleotides with a calculated  $\Delta G^\circ$  in a mid-range tended to have a better effect on *APOB*, than oligonucleotides on either side of this range (Figure 2g), with an optimal  $\Delta G^\circ$  around  $-18$  kcal/mol. Moreover, in all three studies (Figure 2e–g), oligonucleotides of the same length in isolation also display the affinity optimum; the 16-mers in Figure 2g and the 14-mers in Figure 2f and Figure 2g. From this, we conclude that the observed optimum is not caused by length *per se*, but rather by affinity, as indeed predicted by the model.

Finally, in both the *LUC* and *GR* transcripts, oligonucleotides are targeted to three different binding regions (starting positions in the transcripts are listed in Supplementary Material S1 for all oligonucleotides). Which region a given oligonucleotide is targeted to is indicated in Figure 2e,f by either a gray hexagon, triangle, or square behind the point representing that oligonucleotide. This allows us to investigate whether the binding region can influence the position of the affinity optimum. In Figure 2e, four oligonucleotides against *LUC* region A (hexagons) display decreased knockdown efficiency as binding affinity increases (negative slope). In contrast, four oligonucleotides against *LUC* target region B (triangles) display increased knockdown efficiency as binding affinity increases (positive slope). The 13 oligonucleotides against *LUC* target region C



**Figure 3** Schematic drawing of target cleavage illustrating the rationale for introducing the coupling  $k_{OT \rightarrow O+T} = -\alpha \cdot k_{OC \rightarrow O+C}$ . Upon enzyme (E, RNase H) binding to the OT complex the target is cleaved at a rate  $k_{OTE \rightarrow OCE}$ . After cleavage, the right and left parts of the cleaved target will dissociate from the oligonucleotide at (faster) rates  $k_{right}$  and  $k_{left}$ , respectively.

(squares), span a broader range of affinities and by themselves trace out the parabolic relation. Especially for  $\Delta G^\circ < 25$  kcal/mol (Figure 2e), it seems that the different binding regions explain some of the variation in the data. In Figure 2f, both oligonucleotides targeted to binding region A and C by themselves trace out the parabolic relation, and there are no obvious systematic variation between binding regions. In Figure 2g, the oligonucleotides are not focused on specific regions but tiled across the transcript (Supplementary Material S1). This may explain the larger variation around the fitted curve for this data set, which is supported in the model, since differences in accessibility of the target region can be captured as differences in  $k_{O+T \rightarrow OT}$ , which will affect  $K_{dOT}$ . To confirm that a single target region is sufficient to establish the parabolic relation, we designed four oligonucleotides against the same binding region in *PCSK9* and evaluated reduction in transcript levels at two doses by quantitative reverse transcriptase-PCR. As seen in Figure 2h, these four oligonucleotides by themselves demonstrate the optimal affinity, especially for the low dose, even though the span of affinities,  $-17$  to  $-21$  kcal/mol, is relatively narrow (compare Figure 2h with Figure 2e–g).

### The optimal binding affinity is dependent on turnover rates and RNase H levels

Although the experimental data are relatively sparse, it appears as if the optimal affinity may be different between studies (Figure 2e–g). To investigate this further, we examined the model with regard to factors, which are likely to be different between different targets or different cellular contexts (Figure 4). A higher total RNase H concentration ( $E_t$ ) decreases the optimal affinity and increases the potency (Figure 4a). On the other hand, a lower  $E_t$  value increases the optimal affinity and decreases the potency. A fast turnover of the target, *i.e.*, high rates of  $v_{prod}$  and  $k_{T \rightarrow \emptyset}$ , decreases the potency (Figure 4c,d). However, a slow target production increases the optimal affinity, whereas a slow basal target degradation decreases it. This is similar to the findings of microRNAs and siRNAs, where it has been shown that mRNAs with a high turnover rate are more resistant to micro RNA and siRNA silencing.<sup>15</sup> In summary, the model predicts that the optimal affinity is influenced by the target and the context in which the reaction takes place.

### Discussion

*In vivo* a multiplicity of factors influences the potency of an oligonucleotide. These include stability, protein binding, excretion, metabolism, uptake and diffusion into tissue, and uptake into cells and trafficking inside cells. The simple kinetic model presented here, however, provides a sufficient explanation for the experimental observation of increased potency with decreased length.<sup>7,13</sup> Our study suggests that for a given target (with its associated basal turnover rates) and a given cell type (with its RNase H concentration), there is an optimal affinity. With the important coupling between the dissociation rates of the oligonucleotide from intact and cleaved target ( $k_{OT \rightarrow O+T}$  and  $k_{OC \rightarrow O+C}$ ), the model predicts, and the experimental data confirm that oligonucleotides deviating, in either direction, from the optimum tend to have lower potency. It is well known,


and follows almost intuitively from basic principles (and our model) that oligonucleotides with too low affinity will have low potency. They therefore have to be dosed at very high and saturating amounts to bind an appreciable fraction of the target transcripts, and oligonucleotide recycling is not limiting (right-hand side of Figure 2d). That oligonucleotides with too high affinity may also have reduced potency, and that it can be explained by limited recycling, has to our knowledge not been appreciated before (left-hand side of Figure 2d). This insight has practical implications when designing oligonucleotide libraries for drug discovery.

Since the modeling shows that the position of the affinity optimum is parameter dependent (Figure 4), our recommendation for oligonucleotide drug discovery is to initially design a set of oligonucleotides with affinities broadly covering the expected optimum. This allows the optimal affinity for that target and cellular context to be identified, as demonstrated in Figure 2e–h. Subsequent sets of oligonucleotides can then be designed with binding affinities as close to this experimentally identified optimum as possible, keeping in mind that different binding regions may shift the position of the optimum to some extent (Figure 2e–h). This may be due to differences in accessibility, which we speculate could influence  $K_{dOT}$ , although measurements of target structure related to observed optimal affinities will be needed to confirm this relation. We routinely synthesize oligonucleotides with a range of calculated  $\Delta G^\circ$  values from  $-10$  to  $-30$  kcal/mol, and usually find the optimum between  $-16$  and  $-22$  kcal/mol.

While 2' modifications to oligonucleotides are known to increase affinity, other modifications decrease the affinity, *e.g.*, phosphorothioate backbone substitutions.<sup>25</sup> Previously, we considered the use of affinity decreasing modifications as a tradeoff between the loss of affinity and the gain in other beneficial properties (*e.g.*, increased plasma protein binding and cellular uptake). However, our present results indicate that in the context of a highly affine oligonucleotide, using affinity lowering chemistry will be advantageous, since a conjugate or other modification could move a too affine compound back into the affinity optimum.

Although this study has focused entirely on RNase H-recruiting oligonucleotides, the reaction scheme may be similar for siRNAs recruiting RNA induced silencing complex, suggesting that a similar phenomena could be present in this system. Although it is also possible that other mechanisms (*e.g.*, RNA induced silencing complexes preference for certain bases at certain positions) could have a more dominating effect on the potency.

The kinetic model is deliberately limited to contain only the reactions central to enzyme-mediated cleavage of RNA. This is important to avoid inflating the number of parameters. However, additional insights could possibly be gained by expanding the model. Possibilities include adding reactions for oligo-dimerization and self-folding (both of which can be reasonably predicted computationally)<sup>26</sup> or even investigate the effect of lower affinity unintended targets that could theoretically deplete the amount of oligonucleotide.<sup>27</sup> The source code for our model is downloadable under a Creative Commons License that enables others to easily explore these or other extensions.



**Figure 4** The optimal model-predicted affinity is dependent on the physiological parameters. The half-maximal effect concentration ( $EC_{50}$ ) is plotted against the binding affinity, quantified by dissociation constant between the oligonucleotide and the target ( $K_{dOTE}$ ), while varying (a) the total RNase H concentration,  $E_t$ , (b) the coupling constant,  $\alpha$ , (c) the target production,  $v_{prod}$ , (d) the target degradation,  $k_{T \rightarrow \emptyset}$ , (e) the dissociation constant for the OTE complex,  $K_{dOTE}$ , and (f) the rate of target cleavage,  $k_{OTE \rightarrow OCE}$ .

In summary, we provide a simple theoretical explanation for the until now unexplained observation that long (and very affine) oligonucleotides tend to be less potent than shorter (and less affine) versions. We show that the effect is due to affinity rather than length and provide an enzyme kinetic model that explains the observation, without invoking additional complexities such as cellular uptake and protein binding. In our opinion, this demonstrates how examination of basic physical principles can inform one of the most fundamental processes of oligonucleotide based therapeutics: how to design the sequence and its modifications.

## Materials and methods

**Equations governing antisense oligonucleotide-mediated target degradation.** The kinetic model consists of seven ODEs of the seven variables: free target ( $T$ ), free oligonucleotide ( $O$ ), free RNase H ( $E$ ), complex of oligonucleotide and target ( $OT$ ), complex of oligonucleotide, target, and RNase H ( $OTE$ ), complex of cleaved target, oligonucleotide, and RNase H ( $OCE$ ), and complex of cleaved target and oligonucleotide ( $OC$ ):

$$\frac{d[T]}{dt} = v_{prod} - k_{T \rightarrow \emptyset}[T] - k_{O+T \rightarrow OT}[T][O] + k_{OT \rightarrow O+T}[OT] \quad (2)$$

$$\frac{d[O]}{dt} = k_{OT \rightarrow O+T}[OT] - k_{O+T \rightarrow OT}[O][T] + k_{OC \rightarrow O+C}[OC] + k_{T \rightarrow \emptyset}([OT] + [OTE]) \quad (3)$$

$$\frac{d[E]}{dt} = k_{T \rightarrow \emptyset}[OTE] - k_{OT+E \rightarrow OTE}[E][OT] + k_{OTE \rightarrow OT+E}([OTE] + [OCE]) \quad (4)$$

$$\frac{d[OT]}{dt} = k_{O+T \rightarrow OT}[O][T] - k_{OT \rightarrow O+T}[OT] - k_{OT+E \rightarrow OTE}[OT][E] + k_{OTE \rightarrow OT+E}[OTE] - k_{T \rightarrow \emptyset}[OT] \quad (5)$$

$$\frac{d[OTE]}{dt} = k_{OT+E \rightarrow OTE}[E][OT] - k_{OTE \rightarrow OT+E}[OTE] - (k_{T \rightarrow \emptyset} + k_{OTE \rightarrow OCE})[OTE] \quad (6)$$

$$\frac{d[OCE]}{dt} = k_{OTE \rightarrow OCE}[OTE] - k_{OTE \rightarrow OT+E}[OCE] \quad (7)$$

$$\frac{d[OC]}{dt} = k_{OTE \rightarrow OT+E}[OCE] - k_{OC \rightarrow O+C}[OC] \quad (8)$$

Complex formation and breaking are denoted by rate constants  $k$  with subscripts. The target production rate is denoted by  $v_{prod}$  and the degradation rate by  $k_{T \rightarrow \emptyset}$ . The parameter values are listed in **Table 1**.

**Simulations.** An R implementation of the FORTRAN ODE solver vode<sup>28</sup> is used to solve the system of seven ODEs of the model. This solver is a variable-coefficient method where the step-size is calculated at each time point. All calculations and simulations were performed in R (v.3.0.0: R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>) and is described in our ASO-models package obtainable from <https://github.com/lykkep/ASOmodel>, which also contains all data from this manuscript.

**Oligonucleotides.** LNA-modified antisense oligonucleotides were synthesized with complete phosphorothioate backbones using standard phosphoramidite protocols on an Expedite 8900 synthesizer with a Multiple Oligonucleotide Synthesis System unit (ABI, Foster City, CA). The oligonucleotides were purified by reverse-phase high-performance liquid chromatography. Liquid chromatography-mass spectrometry (reverse phase and electrospray ionization-mass spectrometry) were used to verify compound identity and purity. For the full sequences see **Supplementary Material S1**.

**In vitro activity screening of oligonucleotides.** For APOB targeting oligonucleotides, human hepatocellular carcinoma, HuH-7, cells were transfected 24 hours after seeding with oligonucleotides at final concentration of 1 nmol/l, using lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to the manufacturers instructions. Cells were harvested 24 hours after transfection and total RNA isolated using the RNeasy mini kit (Qiagen, Hilden, Germany). The PCSK9 targeting oligonucleotides were

taken up unassisted in the prostate cancer cell line 15PC3, 24 hours after seeding, at final concentrations of 0.06 or 1.5  $\mu\text{mol/l}$ . Cells were harvested after 3 days of uncubation with oligonucleotide and total RNA isolated using the RNeasy mini kit. In both screens, transcript levels were quantified using TaqMan assays (Applied Biosystems, Foster City, CA). The reverse transcription reaction was carried out with random decamers, 0.5 mg total RNA and the M-MLV RT enzyme (Ambion, Naerum, Denmark) according to protocol. Dependent on expression level, first-strand complementary DNA was subsequently diluted five times in nuclease-free water before addition to the reverse transcriptase-PCR reaction mixture. The Applied Biosystems 7500 real-time PCR instrument was used for amplification. Transcript levels were normalized to *glyceraldehyde-3-phosphate dehydrogenase* (*GAPDH*) and presented as percentage change relative to average levels in mock-treated controls. Knockdown data are available in **Supplementary Material S1**.

*From melting temperatures to a nearest-neighbor model for binding affinity.* The melting temperature is defined as the temperature at which half of the oligonucleotides are duplexed with target RNA, and is an often-used experimental measure of duplex stability, although not strictly proportional to binding affinity at physiological conditions.<sup>29</sup> Instead, the standard free energy of binding,  $\Delta G^\circ$  at 37  $^\circ\text{C}$ , is a more physiologically relevant representation of binding affinity, since  $K_{\text{dOT}}$  is logarithmically proportional to  $\Delta G^\circ$ .<sup>30</sup> Also, calorimetric measurement of  $T_m$  by thermal denaturation is affected by oligonucleotide concentration and presence of cations in the buffer,<sup>29</sup> conditions which often differ between studies.<sup>7,13</sup> To allow comparisons between studies reporting  $T_m$  values, and in particular to be able to replace  $T_m$  with  $\Delta G^\circ$ , we therefore constructed a nearest-neighbor model with thermodynamic parameters taken from the literature.<sup>31–33</sup> To validate the model, we used it to calculate  $T_m$  for oligonucleotides from the two studies with historic data (**Figure 2e,f**), where both knockdown data and experimentally measured  $T_m$  values were available. The residual standard error between experimental and calculated  $T_m$  is  $\pm 2.6$   $^\circ\text{C}$  for the *LUC* targeting oligonucleotides<sup>7</sup> and  $\pm 3.5$   $^\circ\text{C}$ <sup>13</sup> for the *GR* targeting oligonucleotides<sup>13</sup> (**Supplementary Material S1**). This is comparable with reported accuracies for nearest-neighbor models,<sup>33</sup> confirming the validity of the nearest-neighbor model-based calculation for these oligonucleotides. Importantly, the nearest-neighbor model also allows calculation of  $\Delta G^\circ$ , based on the same thermodynamic parameters.<sup>34</sup>

## Supplementary material

**Figure S1.** Dose–response curves for different values of  $E_t$ ,  $\alpha$ ,  $v_{\text{prod}}$ ,  $k_{T \rightarrow \emptyset}$ ,  $K_{\text{dOT}}$ ,  $k_{\text{O}+\text{T} \rightarrow \text{OT}}$ ,  $K_{\text{dOTE}}$ ,  $k_{\text{OT}+\text{E} \rightarrow \text{OTE}}$ , and  $k_{\text{OTE} \rightarrow \text{OCE}}$  (top, left to bottom, right).

**Figure S2.** Efficacy and  $\text{EC}_{50}$  is plotted as functions of parameter values for  $E_{\text{tot}}$ ,  $K_{\text{dOTE}}$ ,  $v_{\text{prod}}$ ,  $\alpha$ ,  $k_{\text{O}+\text{T} \rightarrow \text{OT}}$ ,  $k_{\text{OT}+\text{E} \rightarrow \text{OTE}}$ ,  $k_{T \rightarrow \emptyset}$ ,  $k_{\text{OTE} \rightarrow \text{OCE}}$ .

**Figure S3.** The time-trace for the relative total target level when the model is simulated stochastically.

**Figure S4.** Left: Dose–response curves for various values of  $k_{\text{OT} \rightarrow \text{O}+\text{T}}$  (compare to **Supplementary Figure S1**, middle). Right:  $\text{EC}_{50}$  as a function of  $k_{\text{OT} \rightarrow \text{O}+\text{T}}$ . A high value of  $k_{\text{OT} \rightarrow \text{O}+\text{T}}$  corresponds to a low affinity.

**Figure S5.**  $\text{EC}_{50}$  as a function of  $K_{\text{dOT}}$  is fitted on a log-log scale to a parabola.

**Material S1.** Oligonucleotide data.

**Material S2.** mRNA sequences.

**Acknowledgments.** This research is supported by the Danish Strategic Research Council. L.P. declares that she has no competing financial interests. P.H.H., M.W.L., and M.L. are employees of Santaris Pharma A/S, a company developing RNA-targeted therapeutics.

**Author contributions.** M.W.L. designed the laboratory experiments. L.P., P.H.H., and M.L. developed the model and wrote the paper. All authors have approved the final manuscript.

- Walder, RY and Walder, JA (1988). Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. *Proc Natl Acad Sci USA* **85**: 5011–5015.
- Stein, H and Hausen, P (1969). Enzyme from calf thymus degrading the RNA moiety of DNA-RNA Hybrids: effect on DNA-dependent RNA polymerase. *Science* **166**: 393–395.
- Zamecnik, PC and Stephenson, ML (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. *Proc Natl Acad Sci USA* **75**: 280–284.
- Bennett, CF and Swayze, EE (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. *Annu Rev Pharmacol Toxicol* **50**: 259–293.
- Obika, S, Nanbu, D, Hari, Y, Morio, K, In, Y, Ishida, T et al. (1997). Synthesis of 2-O,4-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering. *Tet Lett* **38**, 8735–8738.
- Koshkin, AA, Singh, SK, Nielsen, P, Rajwanshi, VK, Kumar, R, Meldgaard, M et al. (1998). LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. *Tetrahedron* **54**, 3607–3630.
- Frieden, M, Christensen, SM, Mikkelsen, ND, Rosenbohm, C, Thru, CA, Westergaard, M et al. (2003). Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. *Nucleic Acids Res* **31**: 6365–6372.
- Straarup, EM, Fisker, N, Hedjærn, M, Lindholm, MW, Rosenbohm, C, Aarup, V et al. (2010). Short locked nucleic acid antisense oligonucleotides potentially reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. *Nucleic Acids Res* **38**: 7100–7111.
- Manoharan, M (1999). 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. *Biochim Biophys Acta* **1489**: 117–130.
- Hovingh, K, Besseling, J and Kastelein, J (2013). Efficacy and safety of mipomersen sodium (Kynamro). *Expert Opin Drug Saf* **12**: 569–579.
- Swayze, EE and Bhat, B (2007). The medicinal chemistry of oligonucleotides. In: Crooke, ST (ed.). *Antisense Drug Technology*. CRC: Boca Raton, FL.
- Seth, PP, Siwkowski, A, Allerson, CR, Vasquez, G, Lee, S, Prakash, TP et al. (2009). Short antisense oligonucleotides with novel 2'-4' conformationally restricted nucleoside analogues show improved potency without increased toxicity in animals. *J Med Chem* **52**: 10–13.
- Stanton, R, Sciabola, S, Salatto, C, Weng, Y, Moshinsky, D, Little, J et al. (2012). Chemical modification study of antisense gapmers. *Nucleic Acid Ther* **22**: 344–359.
- Herschlag, D (1991). Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. *Proc Natl Acad Sci USA* **88**: 6921–6925.
- Larsson, E, Sander, C and Marks, D (2010). mRNA turnover rate limits siRNA and microRNA efficacy. *Mol Syst Biol* **6**: 433.
- Roth, CM (2005). Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides. *Biophys J* **89**: 2286–2295.
- Brown, KS and Sethna, JP (2003). Statistical mechanical approaches to models with many poorly known parameters. *Phys Rev E Stat Nonlin Soft Matter Phys* **68**(2 Pt 1): 021904.
- Crooke, ST (2008). *Antisense Drug Technologies: Principles, Strategies, and Applications*. CRC Press: Boca Raton, FL.
- Obad, S, dos Santos, CO, Petri, A, Heidenblad, M, Broom, O, Ruse, C et al. (2011). Silencing of microRNA families by seed-targeting tiny LNAs. *Nat Genet* **43**: 371–378.
- Lima, WF, Monia, BP, Ecker, DJ and Freier, SM (1992). Implication of RNA structure on antisense oligonucleotide hybridization kinetics. *Biochemistry* **31**: 12055–12061.
- Patzel, V, zu Putlitz, J, Wieland, S, Blum, HE and Sczakiel, G (1997). Theoretical and experimental selection parameters for HBV-directed antisense RNA are related to increased RNA-RNA annealing. *Biol Chem* **378**: 539–543.
- Jo, JJ, Kim, MJ, Son, JT, Kim, J and Shin, JS (2009). Single-fluorophore monitoring of DNA hybridization for investigating the effect of secondary structure on the nucleation step. *Biochem Biophys Res Commun* **385**: 88–93.
- Rauzan, B, McMichael, E, Cave, R, Sevcik, LR, Ostrosky, K, Whitman, E et al. (2013). Kinetics and thermodynamics of DNA, RNA, and hybrid duplex formation. *Biochemistry* **52**: 765–772.

24. Gillespie, DT (1977). Exact stochastic simulation of coupled chemical reactions. *J Phys Chem* **81**: 2340–2361.
25. Stein, CA, Subasinghe, C, Shinozuka, K and Cohen, JS (1988). Physicochemical properties of phosphorothioate oligodeoxynucleotides. *Nucleic Acids Res* **16**: 3209–3221.
26. Lorenz, R, Bernhart, SH, Höner Zu Siederdisen, C, Tafer, H, Flamm, C, Stadler, PF et al. (2011). ViennaRNA Package 2.0. *Algorithms Mol Biol* **6**: 26.
27. Arvey, A, Larsson, E, Sander, C, Leslie, CS and Marks, DS (2010). Target mRNA abundance dilutes microRNA and siRNA activity. *Mol Syst Biol* **6**: 363.
28. Brown, PN, Byrne, GD and Hindmarsh, AC (1989). VODE, a variable-coefficient ODE solver. *SIAM J Sci Stat Comput* **10**, 1038–1051.
29. Mergny, JL and Lacroix, L (2003). Analysis of thermal melting curves. *Oligonucleotides* **13**: 515–537.
30. Chaires, JB (2008). Calorimetry and thermodynamics in drug design. *Annu Rev Biophys* **37**: 135–151.
31. Sugimoto, N, Nakano, S, Katoh, M, Matsumura, A, Nakamuta, H, Ohmichi, T et al. (1995). Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes. *Biochemistry* **34**: 11211–11216.
32. McTigue, PM, Peterson, RJ and Kahn, JD (2004). Sequence-dependent thermodynamic parameters for locked nucleic acid (LNA)-DNA duplex formation. *Biochemistry* **43**: 5388–5405.
33. Owczarzy, R, You, Y, Groth, CL and Tataurov, AV (2011). Stability and mismatch discrimination of locked nucleic acid-DNA duplexes. *Biochemistry* **50**: 9352–9367.
34. SantaLucia, J Jr (1998). A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. *Proc Natl Acad Sci USA* **95**: 1460–1465.
35. Amirkhanov, NV, Pradeepkumar, PI and Chattopadhyaya, J (2002). Kinetic analysis of the RNA cleavage of the conformationally-constrained oxetane-modified antisense-RNA hybrid duplex by RNase H. *J Chem Soc Perkin Trans 2*: 976–984
36. Lodish, H (2008). *Molecular Cell Biology* (W. H. Freeman: Hampshire, UK).
37. Yang, E, van Nimwegen, E, Zavolan, M, Rajewsky, N, Schroeder, M, Magnasco, M et al. (2003). Decay rates of human mRNAs: correlation with functional characteristics and sequence attributes. *Genome Res* **13**: 1863–1872.
38. Christensen, U, Jacobsen, N, Rajwanshi, VK, Wengel, J and Koch, T (2001). Stopped-flow kinetics of locked nucleic acid (LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions. *Biochem J* **354**(Pt 3): 481–484.



**Molecular Therapy–Nucleic Acids** is an open-access journal published by **Nature Publishing Group**. This work is licensed under a **Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License**. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>

Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (<http://www.nature.com/mtna>)